WuXi Biologics (Cayman) Inc.
WXIBF
Other OTC4.60
USD
- -
- -
ISIN
KYG970081173
CUSIP
G97008117
Return %
Stock
S&P500
1Y
26.72
19.01
3Y
-11.54
65.48
5Y
-74.47
72.20
Capital Structure
FRC
•
in mil. unless spec.Working Capital
FRC
•
in mil. unless spec.Growth Rates
FRC
•
in mil. unless spec.Quarterly Revenue
FRC
•
in mil. unless spec.Quarterly Earnings Per Share
FRC
•
in mil. unless spec.Quarterly Dividends Per Share
FRC
•
in mil. unless spec.- CEO
- Zhisheng Chen
- Full Time Employees
- 13,252
- Sector
- Healthcare
- Industry
- Biotechnology
- Address
- No. 108, Meiliang Road Wuxi JS People's Republic of China 214092
- IPO Date
- Jan 30, 2018
- Website
- wuxibiologics.com
- Similar Companies
- Business
- WuXi Biologics (Cayman) Inc. (Ticker: WXIBF) operates as a leading global contract research, development and manufacturing organization (CRDMO) providing end-to-end biologics solutions from discovery to commercialization; its core services encompass biologics discovery and research including monoclonal antibodies (mAbs), bi- and multi-specific antibodies, antibody-drug conjugates (ADCs), fusion proteins and vaccines; pre-IND and clinical development featuring cell line development via WuXia TM platform, process development, testing and high-throughput formulation with WuXiHigh™2.0 enabling protein concentrations up to 230 mg/mL; clinical and commercial drug substance manufacturing with capacities including multiple 6,000L to 15,000L single-use bioreactors across sites; drug product fill-finish and GMP manufacturing; and advanced bioconjugates via its XDC segment alongside consultation, regulatory affairs and technology platforms like WuXiBody and WuXiUI™ for high-productivity bioprocessing. The company, founded in 2010 and headquartered in Wuxi, China, maintains a subsidiary relationship with WuXi AppTec and employs over 12,500 staff across facilities in China, the United States (including Worcester, MA and Cranbury, NJ), Ireland, Germany, Singapore and expanding to Qatar; it serves global biopharmaceutical clients with operations emphasizing a "Follow the Molecule" and "Win the Molecule" strategy, supporting 864 integrated projects as of mid-2025 including 67 late-stage, 24 commercial manufacturing and portfolios of 326 mAbs, 168 bi-/multispecifics, 225 ADCs, 80 fusion proteins and 25 vaccines. Recent developments include adding a record 86 new integrated projects in the first half of 2025 with over 70% in bi-/multispecifics and ADCs, revenue growth of 16.1% year-over-year to RMB9,953.2 million driven by manufacturing ramp-ups and platforms like EffiX™ microbial expression; capacity expansions such as Ireland's MFG6.2 perfusion increase to 6,000L, Singapore's new modular drug product and XDC facilities operational by late 2025/early 2026, U.S. MFG11 construction with six 6,000L bioreactors, Chengdu's 15,000L-60,000L microbial site and Hangzhou's Asia-first 5,000L single-use scale-out line; asset optimizations via completion of Dundalk, Ireland facility sale to Merck for $500 million in March 2025 and pending divestiture of Leverkusen, Germany drug product site to Terumo Corporation in Q4 2025 to fund share buybacks and Singapore scaling; strategic partnerships like the January 2025 Candid deal for tri-specific T-cell engagers via WuXiBody platform worth up to $925 million plus royalties; and 25 scheduled process performance qualifications (PPQs) for 2025 with a total backlog of US$20.34 billion including US$4.21 billion within three years.
Wuxi Biologics upgraded to Overweight from Neutral at JPMorgan